Drilldown: Medicines

None (3) · Bumetanide (1)

Bumex (1) · Emgality (1) · Kisunla (1) · Vyepti (1)

Anti-amyloid beta (Aβ) monoclonal antibody (1) · Anti-CGRP ligand monoclonal antibody (2) · targets pyroglutamated Aβ in plaques (1) · [[:Category:Loop_diuretics|Loop diuretic]] (1)

None (2) · Humanized IgG1 monoclonal antibody binding CGRP peptide; IV infusion enables fastest onset of any CGRP mAb (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1)

Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1) · Preventive treatment of migraine in adults (1) · Preventive treatment of migraine in adults; episodic cluster headache (1) · '"`UNIQ--vote-00000DDF-QINU`"', '"`UNIQ--vote-00000DE0-QINU`"', '"`UNIQ--vote-00000DE1-QINU`"', '"`UNIQ--vote-00000DE2-QINU`"' (1)

0.5-1 mg PO/IV once or twice daily; titrate to clinical response. Approximate equipotency: bumetanide 1 mg ≈ furosemide 40 mg ≈ torsemide 20 mg (1) · 100 mg IV every 3 months; may increase to 300 mg IV every 3 months (1) · 700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)

0.5, 1, 2 mg tablets; 0.25 mg/mL IV (1) · 100 mg/mL vial for IV infusion (1) · 120 mg/mL prefilled syringe or autoinjector (1) · 350 mg/20 mL vial for IV infusion (1)

1400 mg q4w (1) · 240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 300 mg/quarter (1) · ~10 mg/d typical (1)

IM (1) · Intravenous infusion (1) · IV (1) · IV infusion every 4 weeks (1) · Oral (1) · Subcutaneous (1)

Amyloid PET clearance within months; cognitive benefit over 18 months (1) · Effect demonstrated within 24 hours in some patients (1) · Over weeks (1) · PO 30-60 minutes; IV minutes (1)

3-month dosing interval (1) · 4-6 hours (1) · Monthly dosing (1) · Treatment can be discontinued upon achieving amyloid clearance (1)

None · ~12 hours · ~27 days · ~5 h (caffeine) · '''Autoinduction''': 25-65 hours initially, falling to 12-17 hours after 2-3 weeks of dosing as carbamazepine induces its own CYP3A4 metabolism. Major clinical implication: doses require re-titration after the autoinduction period'"`UNIQ--ref-0000001D-QINU`"' · 0.5-1.5 hours (plasma); pharmacodynamic effect persists 24+ hours'"`UNIQ--ref-000000DE-QINU`"' · 1-1.3 hours'"`UNIQ--ref-000001A1-QINU`"' · 1-1.5 hours'"`UNIQ--ref-00000DE3-QINU`"' · 1-2 hours (parent compound)'"`UNIQ--ref-00000029-QINU`"' · 1-2 hours (parent); 18-30 hours for active metabolite oxypurinol'"`UNIQ--ref-0000030F-QINU`"' · 1-2 hours'"`UNIQ--ref-00000017-QINU`"' · 1-3 days acute, 4-6 days chronic; 4-16 days for norfluoxetine'"`UNIQ--ref-0000004C-QINU`"' · 1-3 hours (normal liver); markedly prolonged in overdose with glutathione depletion'"`UNIQ--ref-00000022-QINU`"' · 1-3 minutes (very short)'"`UNIQ--ref-00000C0F-QINU`"' · 1.4 hours (parent); 13-24 hours for active metabolite canrenone'"`UNIQ--ref-00000354-QINU`"' · 1.5-2 hours (longer in renal failure)'"`UNIQ--ref-00000222-QINU`"' · 1.5-2 hours'"`UNIQ--ref-00000020-QINU`"' · 10-11 hours (benazeprilat, the active metabolite)'"`UNIQ--ref-00000A22-QINU`"' · 11-13 h (immediate-release); 11-16 h (extended-release) · 11-15 hours'"`UNIQ--ref-00000842-QINU`"'

Other values:

Search

100% (IV) (2) · Not formally established (high SC) (1) · ~80-95% (oral; more reliable than furosemide, comparable to torsemide)'"`UNIQ--ref-00000DE4-QINU`"' (1)

Avoid where possible; class concerns as for other loop diuretics.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited data (1) · Limited data; avoid (2)

Rx (2) · Rx; ARIA monitoring required (1) · [[USLegal:Prescription only|Rx-only]] in US (1)